These include cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) homozygous deletion mutation, telomerase reverse transcriptase (TERT) promoter mutation, epidermal growth factor receptor (EGFR) gene amplification, and combined gain of entire chromosome 7 and loss of entire chromosome 10 (+7/−10) as qualifying for the diagnosis of GBM, isocitrate dehydrogenase (IDH)-wildtype [3,4]. The gene discussed is CDKN2A; the disease is glioblastoma.